Last edition
News about "GC Biopharma "
South Korea's GC Biopharma Secures CMO Rights for Curevo's Shingles Vaccine
South Korean biopharmaceutical company GC Biopharma has signed a contract manufacturing agreement with Curevo Vaccine to produce amezosvatein (development name: CRV-101), a recombinant shingles vaccine currently under clinical development.
GC Biopharma | 13/10/2025 | By Dineshwori
Korean Ministry Grants Approval to GC Biopharma's BARYTHRAX Anthrax Vaccine
With the approval by MFDS, BARYTHRAX has become Korea's 39th novel drug.
GC Biopharma | 09/04/2025 | By Abha | 150
GC Biopharma Partners with Novelty Nobility to Jointly Research for Geographic Atrophy Therapies
Under the terms of the agreement, GC Biopharma and Novelty Nobility established a partnership to jointly research and develop antibody-based protein therapeutics for GA throughout all stages of the drug development lifecycle.
GC Biopharma | 28/10/2024 | By Aishwarya | 173
GC Biopharma Rolls Out ALYGLO for Treatment of Primary Humoral Immunodeficiency
ALYGLO, an immune globulin formulation, has met the primary endpoints for both safety and efficacy as established by the FDA-recommended guidelines in our Phase 3 clinical trials.
GC Biopharma | 09/09/2024 | By Aishwarya | 405
GC Biopharma, Hanmi Pharma Secure IND Clearance for Phase 1/2 Clinical Trial
LA-GLA is an innovative new drug for the treatment of Fabry disease as the world's first once-monthly subcutaneous treatment, which is being co-developed by GC Biopharma and Hanmi Pharmaceutical.
GC Biopharma | 03/09/2024 | By Aishwarya | 418
GC Biopharma and Novel Pharma Sanfilippo Syndrome Treatment Receives FDA IND Approval
GC Biopharma and Novel Pharma has announced that its jointly developed MPS IIIA 'GC1130A' treatment has received FDA IND approval.
GC Biopharma | 20/05/2024 | By Aishwarya | 481
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy